Suomeksi
 
 
Monoaminergic neurotransmitters
Valtteri_Kaasinenkuva_PIC.jpg
Valtteri Kaasinen, MD, Phd; specialist in neurology
Division of Clinical Neurosciences, Turku University Hospital
 
GOAL:
The goal of the project is to investigate the role of monoaminergic neurotransmitters in the pathophysiology and treatment of movement disorders and behavioral addictions.
 
GROUP MEMBERS:
  • Juho Joutsa, MD, PhD (postdoc)
  • Juha Järvelä, MD, PhD (postdoc)
  • Mikael Eklund
  • Lauri Heiskanen
  • Emma Honkanen
  • Elina Jaakkola
  • Tuomas Kankare
  • Joonas Majuri
  • Elina Mäkinen
  • Simo Nuuttila
  • Laura Saari
SELECTED PUBLICATIONS:
  1. Saari L, Kivinen K, Gardberg M, Joutsa J, Noponen T, Kaasinen V. Dopamine transporter imaging does not predict the number of nigral neurons in Parkinson disease. Neurology 2017;88:1461-1467.
  2. Majuri J, Joutsa J, Johansson J, Voon V, Alakurtti K, Parkkola R, Lahti T, Alho H, Hirvonen J, Arponen E, Forsback S, Kaasinen V. Dopamine and opioid neurotransmission in behavioral addictions: A comparative PET study in pathological gambling and binge eating. Neuropsychopharmacology 2017; 42:1169-1177.
  3. Isotalo J, Vahlberg T, Kaasinen V. Unchanged long-term rural-to-urban incidence ratio of Parkinson’s disease. Mov Disord 2017; 32:474-475.
  4. Martikainen MH, Päivärinta M, Hietala M, Kaasinen V. Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation. Neurol Genet 2015; 1:e27.
  5. Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppänen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson’s disease. Neurobiol Aging 2015;36:1757-63.
Keywords:
Tags: